{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:05:42Z","timestamp":1789725942427,"version":"4.0.1"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Daptomycin and linezolid may have more favorable safety and efficacy profiles compared to vancomycin and require less therapeutic monitoring. To capitalize on these advantages, the University of Colorado Hospital relaxed prescribing restrictions and updated local guidance for the treatment of Gram-positive infections, resulting in increased daptomycin and linezolid utilization. The objective of this study was to assess the impact of liberalized daptomycin and linezolid use on minimum inhibitory concentrations (MICs) in Gram-positive organisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective, single-center study included all Staphylococcus and Enterococcus isolates across an 8-year period, including a 3-year follow-up period after implementing practice changes. Organisms were categorized as hospital-acquired (HA) if the culture was collected 48\u2005hours after admission. Interrupted time series analyses were performed to measure changes in geometric mean (GM) of MICs before and after implementation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Minimum inhibitory concentrations from 19 160 isolates were evaluated, of which 7224 were HA. Linezolid use increased to 43.7 days of therapy per 1000 patient days (DOT\/1000PD), and daptomycin use increased to 15.7 DOT\/1000PD post-implementation. Linezolid GM MICs trended downward pre-implementation, and the trajectory was unaffected by implementation except in coagulase-negative Staphylococcus (CoNS). Daptomycin GM MICs declined pre-implementation among Enterococcus, but not Staphylococcus. Implementation was associated with a significant slope change in vancomycin-resistant Enterococcus (VRE) and HA CoNS. Resistance rates and MIC distributions were not impacted by implementation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The liberalization of daptomycin and linezolid did not result in clinically relevant increases in resistance. Further studies are needed to confirm the durability of these results, specifically among CoNS and VRE.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofag523","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:47:26Z","timestamp":1787226446000},"source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of Changes in\n                    <i>Staphylococcus<\/i>\n                    and\n                    <i>Enterococcus<\/i>\n                    Resistance Following Reduced Restrictions on Daptomycin and Linezolid"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3338-4176","authenticated-orcid":false,"given":"Blake A","family":"Jennewein","sequence":"first","affiliation":[{"name":"UCHealth University of Colorado Hospital Department of Pharmacy, , Aurora, Colorado ,","place":["USA"]},{"name":"University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences Department of Clinical Pharmacy, , Aurora, Colorado ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0339-6799","authenticated-orcid":false,"given":"Karrine D","family":"Brade","sequence":"additional","affiliation":[{"name":"UCHealth University of Colorado Hospital Department of Pharmacy, , Aurora, Colorado ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9606-9736","authenticated-orcid":false,"given":"Meghan N","family":"Jeffres","sequence":"additional","affiliation":[{"name":"UCHealth University of Colorado Hospital Department of Pharmacy, , Aurora, Colorado ,","place":["USA"]},{"name":"University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences Department of Clinical Pharmacy, , Aurora, Colorado ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9617-2792","authenticated-orcid":false,"given":"Garth C","family":"Wright","sequence":"additional","affiliation":[{"name":"University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences Department of Clinical Pharmacy, , Aurora, Colorado ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1750-6230","authenticated-orcid":false,"given":"Douglas N","family":"Fish","sequence":"additional","affiliation":[{"name":"University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences Department of Clinical Pharmacy, , Aurora, Colorado ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,22]]},"reference":[{"key":"2026091805314100600_ofag523-B1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1179\/2047773215Y.0000000030","article-title":"Antimicrobial resistance: a global multifaceted phenomenon","volume":"109","author":"Prestinaci","year":"2015","journal-title":"Pathog Glob Health"},{"key":"2026091805314100600_ofag523-B2","author":"World Health Organization"},{"key":"2026091805314100600_ofag523-B3","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Antimicrobial Resistance Collaborators","year":"2022","journal-title":"Lancet"},{"key":"2026091805314100600_ofag523-B4","volume-title":"Antibiotic resistance threats in the United States, 2019","author":"CDC","year":"2019"},{"key":"2026091805314100600_ofag523-B5","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.cmi.2022.03.015","article-title":"Staphylococcus aureus bacteraemia mortality: a systematic review and meta-analysis","volume":"28","author":"Bai","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2026091805314100600_ofag523-B6","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1080\/21505594.2021.1878688","article-title":"Pathogenicity and virulence of Staphylococcus aureus","volume":"12","author":"Cheung","year":"2021","journal-title":"Virulence"},{"key":"2026091805314100600_ofag523-B7","doi-asserted-by":"crossref","first-page":"8097","DOI":"10.1128\/AEM.05316-11","article-title":"Expression of virulence factors by Staphylococcus aureus grown in serum","volume":"77","author":"Oogai","year":"2011","journal-title":"Appl Environ Microbiol"},{"key":"2026091805314100600_ofag523-B8","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1016\/S0140-6736(22)02185-7","article-title":"Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"400","author":"GBD 2019 Antimicrobial Resistance Collaborators","year":"2022","journal-title":"Lancet"},{"key":"2026091805314100600_ofag523-B9","volume-title":"Global antimicrobial resistance and use surveillance system (GLASS) report 2022","year":"2022"},{"key":"2026091805314100600_ofag523-B10","volume-title":"Antimicrobial resistance threats in the United States, 2021-2022","author":"CDC","year":"2025"},{"key":"2026091805314100600_ofag523-B11","doi-asserted-by":"crossref","first-page":"2001628","DOI":"10.2807\/1560-7917.ES.2021.26.45.2001628","article-title":"Hospital-acquired infections caused by enterococci: a systematic review and meta-analysis, WHO European region, 1 January 2010 to 4 February 2020","volume":"26","author":"Brinkwirth","year":"2021","journal-title":"Euro Surveill"},{"key":"2026091805314100600_ofag523-B12","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3390\/antibiotics11070857","article-title":"Enterococcus virulence and resistant traits associated with its permanence in the hospital environment","volume":"11","author":"Geraldes","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"2026091805314100600_ofag523-B13","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa1914433","article-title":"Multidrug-resistant bacterial infections in U.S. hospitalized patients, 2012-2017","volume":"382","author":"Jernigan","year":"2020","journal-title":"N Engl J Med"},{"key":"2026091805314100600_ofag523-B14","doi-asserted-by":"crossref","first-page":"1800516","DOI":"10.2807\/1560-7917.ES.2018.23.46.1800516","article-title":"Prevalence of healthcare-associated infections, estimated incidence and composite antimicrobial resistance index in acute care hospitals and long-term care facilities: results from two European point prevalence surveys, 2016 to 2017","volume":"23","author":"Suetens","year":"2018","journal-title":"Euro Surveill"},{"key":"2026091805314100600_ofag523-B15","doi-asserted-by":"crossref","first-page":"762","DOI":"10.3390\/antibiotics9110762","article-title":"The evolving reduction of vancomycin and daptomycin susceptibility in MRSA-salvaging the gold standards with combination therapy","volume":"9","author":"Morrisette","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"2026091805314100600_ofag523-B16","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1093\/cid\/cit614","article-title":"Methicillin-resistant Staphylococcus aureus therapy: past, present, and future","volume":"58 Suppl 1","author":"Rodvold","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2026091805314100600_ofag523-B17","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1128\/AAC.44.4.1062-1066.2000","article-title":"In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains","volume":"44","author":"Rybak","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"2026091805314100600_ofag523-B18","doi-asserted-by":"crossref","first-page":"4289","DOI":"10.1128\/AAC.00417-08","article-title":"Serial daptomycin selection generates daptomycin-nonsusceptible Staphylococcus aureus strains with a heterogeneous vancomycin-intermediate phenotype","volume":"52","author":"Camargo","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2026091805314100600_ofag523-B19","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1128\/AAC.50.3.1079-1082.2006","article-title":"Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus","volume":"50","author":"Cui","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2026091805314100600_ofag523-B20","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2026091805314100600_ofag523-B21","doi-asserted-by":"crossref","first-page":"5841","DOI":"10.1128\/AAC.00227-16","article-title":"Daptomycin improves outcomes regardless of vancomycin MIC in a propensity-matched analysis of methicillin-resistant Staphylococcus aureus bloodstream infections","volume":"60","author":"Claeys","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2026091805314100600_ofag523-B22","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus","volume":"355","author":"Fowler","year":"2006","journal-title":"N Engl J Med"},{"key":"2026091805314100600_ofag523-B23","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/cid\/cit112","article-title":"Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration &gt;1\u2005mg\/L: a matched cohort study","volume":"56","author":"Murray","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2026091805314100600_ofag523-B24","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1093\/cid\/ciaa1572","article-title":"Comparative effectiveness of switching to daptomycin versus remaining on vancomycin among patients with methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections","volume":"72","author":"Schweizer","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026091805314100600_ofag523-B25","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/cid\/cir764","article-title":"Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study","volume":"54","author":"Moore","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2026091805314100600_ofag523-B26","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jgar.2020.12.009","article-title":"Meta-analysis of vancomycin versus linezolid in pneumonia with proven methicillin-resistant Staphylococcus aureus","volume":"24","author":"Kato","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"2026091805314100600_ofag523-B27","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1086\/318486","article-title":"Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study","volume":"32","author":"Rubinstein","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2026091805314100600_ofag523-B28","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1128\/AAC.49.6.2260-2266.2005","article-title":"Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections","volume":"49","author":"Weigelt","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2026091805314100600_ofag523-B29","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/cid\/cir895","article-title":"Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study","volume":"54","author":"Wunderink","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2026091805314100600_ofag523-B30","first-page":"CD008056","article-title":"Linezolid versus vancomycin for skin and soft tissue infections","volume":"2016","author":"Yue","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2026091805314100600_ofag523-B31","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1177\/0897190019834369","article-title":"Vancomycin area under the curve dosing and monitoring at an academic medical center: transition strategies and lessons learned","volume":"33","author":"Gregory","year":"2020","journal-title":"J Pharm Pract"},{"key":"2026091805314100600_ofag523-B32","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s40265-017-0764-7","article-title":"The whole price of vancomycin: toxicities, troughs, and time","volume":"77","author":"Jeffres","year":"2017","journal-title":"Drugs"},{"key":"2026091805314100600_ofag523-B33","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American society of health-system pharmacists, the Infectious Diseases Society of America, the pediatric infectious diseases society, and the society of infectious diseases pharmacists","volume":"77","author":"Rybak","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"2026091805314100600_ofag523-B34","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s40261-021-01077-8","article-title":"Exploratory cost-effectiveness analysis for treatment of methicillin-resistant Staphylococcus aureus bloodstream infections: is linezolid or daptomycin favored over vancomycin?","volume":"41","author":"Vu","year":"2021","journal-title":"Clin Drug Investig"},{"key":"2026091805314100600_ofag523-B35","doi-asserted-by":"publisher","first-page":"ofae217","DOI":"10.1093\/ofid\/ofae217","article-title":"Counting the cost of daptomycin versus vancomycin in hospitalized patients: a cost minimization analysis","volume":"11","author":"Wagner","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2026091805314100600_ofag523-B36","doi-asserted-by":"crossref","first-page":"664199","DOI":"10.3389\/fmicb.2021.664199","article-title":"Low proportion of linezolid and daptomycin resistance among bloodborne vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus infections in Europe","volume":"12","author":"Markwart","year":"2021","journal-title":"Front Microbiol"},{"key":"2026091805314100600_ofag523-B37","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13756-020-00714-9","article-title":"The global prevalence of daptomycin, tigecycline, quinupristin\/dalfopristin, and linezolid-resistant Staphylococcus aureus and coagulase-negative staphylococci strains: a systematic review and meta-analysis","volume":"9","author":"Shariati","year":"2020","journal-title":"Antimicrob Resist Infect Control"},{"key":"2026091805314100600_ofag523-B38","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01926-18","article-title":"Evolution of daptomycin resistance in coagulase-negative staphylococci involves mutations of the essential two-component regulator WalKR","volume":"63","author":"Jiang","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026091805314100600_ofag523-B39","doi-asserted-by":"crossref","first-page":"e3000987","DOI":"10.1371\/journal.pbio.3000987","article-title":"Daptomycin treatment impacts resistance in off-target populations of vancomycin-resistant Enterococcus faecium","volume":"18","author":"Kinnear","year":"2020","journal-title":"PLoS Biol"},{"key":"2026091805314100600_ofag523-B40","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/cid\/ciy089","article-title":"Clonal emergence of invasive multidrug-resistant Staphylococcus epidermidis deconvoluted via a combination of whole-genome sequencing and microbiome analyses","volume":"67","author":"Li","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2026091805314100600_ofag523-B41","first-page":"mgen001055","article-title":"Emergence of linezolid-resistant Enterococcus faecium in a tertiary hospital in Copenhagen","volume":"9","author":"Misiakou","year":"2023","journal-title":"Microb Genom"},{"key":"2026091805314100600_ofag523-B42","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1093\/jac\/dkq238","article-title":"Emergence of linezolid-resistant coagulase-negative Staphylococcus in a cancer centre linked to increased linezolid utilization","volume":"65","author":"Mulanovich","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2026091805314100600_ofag523-B43","doi-asserted-by":"crossref","first-page":"118.e1","DOI":"10.1016\/j.cmi.2016.10.003","article-title":"Association of daptomycin use with resistance development in Enterococcus faecium bacteraemia\u2014a 7-year individual and population-based analysis","volume":"23","author":"Egli","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"2026091805314100600_ofag523-B44","doi-asserted-by":"crossref","first-page":"e1076","DOI":"10.1016\/j.ijid.2013.02.019","article-title":"In vivo acquired daptomycin resistance during treatment of methicillin-resistant Staphylococcus aureus endocarditis","volume":"17","author":"Dortet","year":"2013","journal-title":"Int J Infect Dis"},{"key":"2026091805314100600_ofag523-B45","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1128\/JCM.44.2.595-597.2006","article-title":"Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis","volume":"44","author":"Marty","year":"2006","journal-title":"J Clin Microbiol"},{"key":"2026091805314100600_ofag523-B46","doi-asserted-by":"crossref","first-page":"e01800\u201318","DOI":"10.1128\/AAC.01800-18","article-title":"Impact of an antimicrobial stewardship intervention on within- and between-patient daptomycin resistance evolution in vancomycin-resistant Enterococcus faecium","volume":"63","author":"Kinnear","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026091805314100600_ofag523-B47","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1128\/AAC.49.4.1664-1665.2005","article-title":"Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy","volume":"49","author":"Lewis","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2026091805314100600_ofag523-B48","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1128\/AAC.05702-11","article-title":"Resistance to linezolid caused by modifications at its binding site on the ribosome","volume":"56","author":"Long","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2026091805314100600_ofag523-B49","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1128\/AAC.02803-15","article-title":"Linezolid surveillance results for the United States (LEADER surveillance program 2014)","volume":"60","author":"Flamm","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2026091805314100600_ofag523-B50","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1179\/joc.2011.23.2.71","article-title":"Eight-year (2002-2009) summary of the Linezolid (Zyvox\u00ae annual appraisal of potency and Spectrum; ZAAPS) program in European countries","volume":"23","author":"Ross","year":"2011","journal-title":"J Chemother"},{"key":"2026091805314100600_ofag523-B51","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1128\/AAC.01098-07","article-title":"Linezolid resistance in Staphylococcus aureus: gene dosage effect, stability, fitness costs, and cross-resistances","volume":"52","author":"Besier","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2026091805314100600_ofag523-B52","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1086\/511640","article-title":"Measurement of adult antibacterial drug use in 130 US hospitals: comparison of defined daily dose and days of therapy","volume":"44","author":"Polk","year":"2007","journal-title":"Clin Infect Dis"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag523\/70762548\/ofag523.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/9\/ofag523\/70762548\/ofag523.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/9\/ofag523\/70762548\/ofag523.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T09:32:08Z","timestamp":1789723928000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag523\/8768525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,22]]},"references-count":52,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag523","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,8,22]]},"article-number":"ofag523"}}